Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

MPH Health Care Aktie 57233620 / DE000A289V03

20.11.2025 08:30:03

EQS-News: MPH Health Care AG publishes figures for the third quarter of 2025: Equity (NAV) amounts to EUR 194.2 million, corresponding to EUR 45.36 per share. The equity ratio fell slightly to 92.8%

EQS-News: MPH Health Care AG / Key word(s): 9 Month figures/Quarterly / Interim Statement
MPH Health Care AG publishes figures for the third quarter of 2025: Equity (NAV) amounts to EUR 194.2 million, corresponding to EUR 45.36 per share. The equity ratio fell slightly to 92.8%

20.11.2025 / 08:30 CET/CEST
The issuer is solely responsible for the content of this announcement.


MPH Health Care AG publishes figures for the third quarter of 2025:

Equity (net asset value) amounts to EUR 194.2 million, corresponding to EUR 45.36 per share. The equity ratio fell slightly to 92.8% (31 December 2024: 95.5%).

Berlin, 20th November 2025 - MPH Health Care AG (ISIN: DE000A289V03) announces its preliminary IFRS consolidated results for the third quarter of 2025. According to this, equity decreased by 30% from EUR 277.9 million as of 31 December 2024 to EUR 194.2 million as of 30 September 2025. Net asset value (NAV) per share fell from EUR 64.90 (31 December 2024) to EUR 45.36 as of 30 September 2025.

The IFRS net result for the period decreased from EUR 54.5 million as of 30 September 2024 to EUR -78.5 million as of 30 September 2025. This result is due to the accounting valuations of the investments as at the reporting date, which do not affect cashflow. MPH AG is an investment company whose investments are reported as financial assets under the balance sheet item ‘Financial assets’ and are measured at fair value through profit or loss on the balance sheet date.

The equity ratio fell slightly from 95.5% to 92.8% and remains at a very high level.

The financial situation has improved compared to the previous year. From 1 January to 30 September 2025, operating cashflow amounted to EUR 2,156 thousand (previous year: EUR 2,073 thousand) and net cashflow amounted to EUR 2,421 thousand (previous year: EUR -5,131 thousand).

The fair value losses are mainly due to the sharp decline in the share price of our listed investment CR Energy AG, which filed for (preliminary) insolvency proceedings with the competent local court in Potsdam in June 2025. The main proceedings were opened on 1 September 2025. The price of CR shares fell from EUR 4.78 on 31 December 2024 to EUR 0.37 on 30 September 2025.

The M1 Kliniken AG investment continued its growth trajectory in the first nine months of 2025, once again increasing both revenue and earnings. Consistently implemented efficiency measures and the targeted expansion of medical capacities remain key priorities and are making a significant contribution to further improving results. IFRS consolidated revenue from January to September 2025 amounted to EUR 274.3 million, compared with EUR 257.2 million in the same period of the previous year. This represents an increase of 6.7%. The consolidated EBIT margin increased to 8.9% in this period (same period of the previous year: 8.6%). Operating profit (EBIT) increased to EUR 24.5 million (previous year: EUR 22.1 million), representing a growth of +11%. Earnings before taxes (EBT) rose by around 10% to EUR 24.4 million as of 30 September 2025.

The Beauty segment remains the Group's most important growth driver. The positive development already recorded in the first half of the year continued convincingly in the third quarter of 2025. In the first nine months of 2025, the segment continued to benefit from efficiency gains through optimised processes and higher utilisation of medical capacities. EBIT in the „Beauty“ segment increased disproportionately by around 30% to EUR 21.1 million.

The price of M1 Kliniken shares fell from EUR 16.60 on 31 December 2024 to EUR 14.30 on 30 September 2025.

M1 Kliniken AG remains on course for growth and aims to increase revenue in the high-margin beauty segment to EUR 200–300 million per year by 2029, with a sustainable EBIT margin of at least 20%. The group is thus consistently pursuing its goal of establishing M1 Med Beauty as the world's leading brand for aesthetic medicine.

At this year's Annual General Meeting of MPH Health Care AG on 17 July 2025, it was resolved to distribute a dividend of EUR 1.20 per dividend-bearing share, as in the previous year, and to carry forward the remaining amount of the 2024 net profit of EUR 72.5 million to new account.

About MPH Health Care AG:

MPH Health Care AG is an investment company with a strategic focus on the acquisition, development and sale of companies and company shares, particularly in growth segments of the healthcare market. This includes both insurance-financed and privately financed segments. However, MPH also aims to exploit potential opportunities in high-growth and high-yield sectors outside the healthcare market.



Contact:
Patrick Brenske, Management Board
Corporate Communications
E-Mail: ir@mph-ag.de


20.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: MPH Health Care AG
Grünauer Strasse 5
12557 Berlin
Germany
Phone: 030 / 863 21 45 60
Fax: 030 / 863 21 45 69
E-mail: info@mph-ag.de
Internet: www.mph-ag.de
ISIN: DE000A289V03
WKN: A289V0
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2232688

 
End of News EQS News Service

2232688  20.11.2025 CET/CEST

Analysen zu MPH Health Care AG Inhaber-Akt Nach Kapitalherabsetzung

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Kommt 2025 der grosse KI-Crash? Tim Schäfer über Nvidia, OpenAI & die Parallelen zu 1929

Könnte der aktuelle KI-Boom an den Börsen in einen Crash münden – ähnlich wie 1929 oder zur Dotcom-Blase? 📉💻

In diesem spannenden Gespräch mit Tim Schäfer sprechen wir über Parallelen zum historischen Börsencrash, die massive Überbewertung vieler Tech- und KI-Aktien wie Nvidia, Palantir oder Microsoft – und was das für Langfristanleger bedeutet. Ist der Hype finanziell überhaupt noch tragbar? Wie positionieren sich Insider und Grossinvestoren wie Warren Buffett oder Peter Thiel?

💬 Welche Risiken birgt der aktuelle KI-Hype?
💬 Was sagen Insiderverkäufe und Bewertungen über die Marktlage?
💬 Wie sollte man sich als Privatanleger jetzt aufstellen?

Ein Interview für alle, die sich fragen: Ist das noch Wachstum oder schon Wahnsinn?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Kommt 2025 der grosse KI-Crash? Tim Schäfer über Nvidia, OpenAI & die Parallelen zu 1929

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 13’066.51 19.89 U5BSSU
Short 13’334.71 13.85 B6CSKU
Short 13’820.84 8.98 SSUB2U
SMI-Kurs: 12’543.06 20.11.2025 17:30:18
Long 12’035.25 19.28 SZ8B6U
Long 11’760.87 13.62 SHFB5U
Long 11’281.33 8.98 SJ9BIU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com